(Q33426123)

26 July 2017

1 reference

title

Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection (English)

1 reference

26 July 2017

1 reference

Horatio B Fung

1

1 reference

PubMed ID

12462284

26 July 2017

Elizabeth A Stone

series ordinal

2

1 reference

PubMed ID

12462284

26 July 2017

Frank J Piacenti

series ordinal

3

1 reference

26 July 2017

1 October 2002

1 reference

26 July 2017

Clinical Therapeutics

1 reference

26 July 2017

24

1 reference

26 July 2017

10

1 reference

26 July 2017

1515-1548

1 reference

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

An anti-HIV strategy combining chemotherapy and therapeutic vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming immune stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980058-3

7 January 2021

10.1016/S0149-2918(02)80058-3

Identifiers

DOI

1 reference

26 July 2017

1 reference

PubMed ID

12462284